Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Virtual Conference 2021 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2132 Survival and Prognosis in Patients with Duodeno-Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1 Syndrome

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is an inherited syndrome, affecting multiple endocrine glands. Duodeno-pancreatic neuroendocrine tumors (DP-NET) represent the most frequent type of NET in MEN1. Their prognosis and treatment strategy is debated.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Modica R

Authors: Modica R, Lo Calzo F, De Cicco F, Bottiglieri F, Sciammarella C,

Keywords: neuroendocrine tumor, MEN1 syndrome, duodeno pancreatic tumor.,

#1770 Cytokines as Predictive Factors of Response to Somatostatin Analogues in Patients with Neuroendocrine Tumour

Introduction: The somatostatin analogues are a major therapeutic advance in neuroendocrine tumor (NET) treatment and have multiple modulatory effects on the immune system.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Sciammarella C

Authors: Sciammarella C, Grimaldi A, Circelli L, Modica R, Pizza G,

Keywords: cytokines, neuroendocrine, cell,

#1758 Efficacy and Safety of Low Dose Vandetanib in Metastatic Medullary Thyroid Cancer

Introduction: Medullary thyroid cancer (MTC) is an aggressive thyroid malignancy. Vandetanib is a tyrosine kinase inhibitor approved for locally advanced or metastatic MTC, administered orally 300 mg/daily. Diarrhea, hypertension and QT prolongation are common side effects and may require withdrawal or dose reduction.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Modica R

Authors: Modica R, Pizza G, Lo Calzo F, De Cicco F, Sciammarella C,

Keywords: medullary thyroid cancer, tyrosine kinase inhibitor,

#1756 Somatostatin Analogs in Patients with Multiple Endocrine Neoplasia Type 1 and Zollinger-Ellison Syndrome: Efficacy and Safety

Introduction: Zollinger-Ellison syndrome (ZES) can cause severe complications. In multiple endocrine neoplasia type 1 (MEN1) related ZES, surgery has a controversial role and proton pump inhibitors (PPI) are usually first-line therapy, although some concerns regarding long-term use. Somatostatin analogs (SSA) both reduce hypergastrinemia and have an antiproliferative role.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Modica R

Authors: Modica R, Pizza G, Lo Calzo F, De Cicco F, Sciammarella C,

Keywords: somatostatin analogs, MEN1, Zollinger-Ellison syndrome,

#1109 Expression and Role of the CXCR4/CXCL12/CXCR7 Axis and Crosstalk with the mTOR Pathway in Neuroendocrine Tumors (NETs)

Introduction: Chemokine receptor CXCR4 has been shown to signal on mTOR pathway in gastric and renal cancer. CXCR4 interacts with the chemokine CXCL12 to exert proliferative and chemotactic effects.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Sciammarella C

Authors: Sciammarella C, Circelli L, Guadagno E, Tafuto S, Del Basso De Caro M,

Keywords: chemokine, mtor, nets, clinical outcome.,

Abstract Submissions in 2022

Abstract submissions for 2022 will open in September 2021!

 

The 19th Annual ENETS Conference in 2022 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Virtual Conference 2021 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.